Bill > S2115

This bill, the Medical Supply Chain Resiliency Act, aims to improve the resilience of the United States' medical supply chain. The key provisions of the bill include: 1. Authorizing the President to negotiate and enter into "Trusted Trade Partner Agreements" with countries that have demonstrated a commitment to maintaining open trade in medical goods, adhering to existing trade agreements, reducing unnecessary trade barriers, protecting intellectual property rights, and promoting good regulatory practices. These agreements can provide for the reduction or elimination of tariffs, the diversification of supplier networks, the harmonization of regulatory procedures, increased access to government procurement markets, and other measures to strengthen the medical supply chain. 2. Establishing a congressional oversight and review process, where the President must notify Congress before initiating negotiations, consult with relevant Congressional committees during the negotiations, and submit a report for Congressional review before entering into any Trusted Trade Partner Agreement. Congress has the authority to disapprove an agreement through a joint resolution. 3. Requiring the United States Trade Representative to monitor the compliance of Trusted Trade Partners with their commitments under the agreements, and enabling the President to take action, such as suspending the agreement or entering into a new agreement with the partner, if the partner fails to comply. The overall goal of the bill is to enhance the national security and public health of the United States by diversifying and strengthening the medical supply chain, particularly in response to potential future public health emergencies.